The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity
NCT ID: NCT07052539
Last Updated: 2025-07-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
60 participants
OBSERVATIONAL
2022-07-22
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of High Protein Diet Versus GFR Based Protein Diet in Heart Failure Patients With Renal Insufficiency
NCT03213821
Renal Hemodynamics in Patients With HFpEF
NCT03672591
Kidney Function in People With Cystic Fibrosis in the Era of HEMT
NCT06595420
Effects of a Reduction in Kidney Function on Cardiovascular Structure and Function: A Prospective Study of Kidney Donors
NCT01028703
New Heart Failure Biomarkers in Early Stage Chronic Kidney Disease-Mineral and Bone Disorder
NCT03307707
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy Participants
High protein and sodium meal
Meal with 1g/kg protein content and 3900mg sodium
Obese Participants without HFpEF
High protein and sodium meal
Meal with 1g/kg protein content and 3900mg sodium
HFpEF and Obese Participants
High protein and sodium meal
Meal with 1g/kg protein content and 3900mg sodium
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
High protein and sodium meal
Meal with 1g/kg protein content and 3900mg sodium
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal kidney function
* No heart failure
* BMI 25-30kg/m2
* Adults 18-75 years old
* eGFR \>= 60 mL/min/1.73m2
* BMI \> 35 kg/m2
* Adults 18-75 years old
* eGFR \>= 60 mL/min/1.73m2
* BMI \> 35 kg/m2
* Diagnosis of HFpEF (chart diagnosis, LVEF \> 55% on echo, H2FPEF score 6-9 or HFA-PEFF score 5 or 6
Exclusion Criteria
* eGFR\<60mL/min/1.73m2
* Pregnancy or breast feeding
* History of cutaneous or allergic reaction to iodine-based products of contrast dyes
* Hemoglobin levels \<7mg/dL
* Acute illness or hospitalization event within 3 months
* Unable to stop NSAIDs
* Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism
* Current use of nicotine or recreational drugs, chronic drinker
Criteria for Cohort 2: Obese Participants without HFpEF
* Diagnosis of Heart Failure
* Diagnosis of chronic illness
* eGFR\<60mL/min/1.73m2
* Pregnancy or breast feeding
* History of cutaneous or allergic reaction to iodine-based products of contrast dyes
* Hemoglobin levels \<7mg/dL
* Acute illness or hospitalization event within 3 months
* Unable to stop NSAIDs
* Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism
* Current use of nicotine or recreational drugs, chronic drinker
Criteria for Cohort 3: HFpEF and Obese Participants
* NYHA class III/IV
* Urinary retention screen +
* Mobility issues
* History of RRT or kidney transplant
* Acute illness/hospitalization in the past 3 months
* History of cancer, chemo, or XRT
* Pregnant/breastfeeding
* History of allergies to contrast
* Hemoglobin \< 7
* Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism
* Unable to stop NSAIDs
* Current use of nicotine or recreational drugs, chronic drinker
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Mississippi Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marissa C Tio, MD
Role: PRINCIPAL_INVESTIGATOR
University of Mississippi Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Mississippi Medical Center
Jackson, Mississippi, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-1040
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.